X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CADILA HEALTHCARE ALKEM LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x - 20.1 - View Chart
P/BV x 7.0 4.8 147.7% View Chart
Dividend Yield % 0.6 0.9 71.6%  

Financials

 ALKEM LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CADILA HEALTHCARE
Mar-18
ALKEM LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,589558 284.8%   
Low Rs1,232362 340.8%   
Sales per share (Unadj.) Rs417.5116.3 359.0%  
Earnings per share (Unadj.) Rs56.317.9 315.1%  
Cash flow per share (Unadj.) Rs64.723.1 279.7%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.8 118.3%  
Book value per share (Unadj.) Rs292.985.4 342.9%  
Shares outstanding (eoy) m119.571,023.74 11.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.0 85.5%   
Avg P/E ratio x25.125.7 97.4%  
P/CF ratio (eoy) x21.819.9 109.7%  
Price / Book Value ratio x4.85.4 89.5%  
Dividend payout %22.619.6 115.2%   
Avg Mkt Cap Rs m168,653470,664 35.8%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m9,17118,545 49.5%   
Avg. sales/employee Rs ThNM10,072.7-  
Avg. wages/employee Rs ThNM1,569.1-  
Avg. net profit/employee Rs ThNM1,547.7-  
INCOME DATA
Net Sales Rs m49,915119,049 41.9%  
Other income Rs m1,6451,132 145.3%   
Total revenues Rs m51,561120,181 42.9%   
Gross profit Rs m8,48228,475 29.8%  
Depreciation Rs m1,0065,388 18.7%   
Interest Rs m671911 73.6%   
Profit before tax Rs m8,45123,308 36.3%   
Minority Interest Rs m-114628 -18.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6065,644 28.5%   
Profit after tax Rs m6,73118,292 36.8%  
Gross profit margin %17.023.9 71.0%  
Effective tax rate %19.024.2 78.5%   
Net profit margin %13.515.4 87.8%  
BALANCE SHEET DATA
Current assets Rs m27,06282,005 33.0%   
Current liabilities Rs m15,32460,720 25.2%   
Net working cap to sales %23.517.9 131.5%  
Current ratio x1.81.4 130.8%  
Inventory Days Days6773 90.9%  
Debtors Days Days4198 42.0%  
Net fixed assets Rs m12,61083,703 15.1%   
Share capital Rs m2391,024 23.3%   
"Free" reserves Rs m34,49086,421 39.9%   
Net worth Rs m35,02787,445 40.1%   
Long term debt Rs m1,21225,551 4.7%   
Total assets Rs m54,387180,653 30.1%  
Interest coverage x13.626.6 51.2%   
Debt to equity ratio x00.3 11.8%  
Sales to assets ratio x0.90.7 139.3%   
Return on assets %13.610.6 128.0%  
Return on equity %19.220.9 91.9%  
Return on capital %24.922.0 113.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56342,683 15.4%   
Fx outflow Rs m3,01211,242 26.8%   
Net fx Rs m3,55231,441 11.3%   
CASH FLOW
From Operations Rs m7,2599,193 79.0%  
From Investments Rs m1,864-9,737 -19.1%  
From Financial Activity Rs m-9,273515 -1,800.5%  
Net Cashflow Rs m-150-29 517.2%  

Share Holding

Indian Promoters % 66.9 74.8 89.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.3 398.8%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 11.0 -  
Shareholders   68,381 44,069 155.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS